Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

Core Viewpoint - Dynavax Technologies Corporation is urging stockholders to vote "FOR" its four director nominees in response to a proxy contest initiated by Deep Track Capital, emphasizing the company's strong financial performance and strategic direction [1][2][3] Financial Performance - Dynavax has achieved total stockholder returns of 267% over the past five years, significantly outperforming the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index [3][9] - The company reported a substantial increase in HEPLISAV-B® net product revenue, growing from $36 million in 2020 to a record $268 million in 2024, representing a 65% compound annual growth rate [9] - Anticipated net product revenue for HEPLISAV-B® in 2025 is projected to be between $305 million and $325 million, with expectations for the U.S. hepatitis B adult vaccine market to peak at over $900 million by 2030 [9] Strategic Direction - Dynavax is executing a disciplined capital allocation strategy, including a $200 million share repurchase program, of which $128.8 million has already been executed as of the end of Q1 2025 [8][9] - The company has refocused its portfolio on vaccines, successfully launching HEPLISAV-B® and advancing its differentiated vaccine pipeline [7][9] - Dynavax's board has been programmatically refreshed, with new directors possessing extensive experience in biotechnology and vaccine development [11][12] Governance and Board Composition - The board nominees proposed by Dynavax are described as highly qualified, with significant experience in the biotechnology sector, contrasting with the unqualified candidates put forth by Deep Track [3][15][18] - The board has implemented corporate governance enhancements, including a proposal to declassify the board, which aims to improve accountability and responsiveness to stockholders [12][19] Proxy Contest Context - Deep Track Capital is attempting to gain control of the Dynavax board to implement a short-term strategy that the company believes would be detrimental to long-term value creation [5][14][17] - Dynavax has made multiple attempts to reach a settlement with Deep Track to avoid a costly proxy contest, but these efforts have been met with resistance [16][17]